These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8452114)

  • 41. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
    Hesketh PJ
    Support Care Cancer; 1994 Sep; 2(5):286-92. PubMed ID: 8000724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Kelsen DP; Reilly LK; Groshen S; Bosl GJ; Kalman LA
    Cancer; 1985 Feb; 55(3):527-34. PubMed ID: 3880660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
    Köseoglu V; Kürekçi AE; Sarici U; Atay AA; Ozcan O
    Eur J Pediatr; 1998 Oct; 157(10):806-10. PubMed ID: 9809818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin.
    Stephens SH; Silvey VL; Wheeler RH
    Cancer; 1990 Aug; 66(3):443-6. PubMed ID: 2194642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination antiemetic therapy in cisplatin-induced nausea and vomiting.
    Krebs HB; Myers MB; Wheelock JB; Goplerud DR
    Cancer; 1985 Jun; 55(11):2645-8. PubMed ID: 3888367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Kirchner V; Aapro M; Alberto P; O'Grady P; Busch B; Boyce M
    Ann Oncol; 1993 Jun; 4(6):481-4. PubMed ID: 8353090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting.
    Póka R; Hernádi Z; Juhász B; Lampé L
    Int J Gynaecol Obstet; 1993 Jul; 42(1):19-24. PubMed ID: 8103470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
    González Barón M; Chacón JI; García Girón C; Ordóñez Gallego A; García de Paredes ML; Feliu J; Zamora P; Herranz C; Garrido P; Artal A
    Acta Oncol; 1991; 30(5):623-7. PubMed ID: 1892680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group.
    Conroy T; Cappelaere P; Fabbro M; Fauser AA; Splinter TA; Spielmann M; Schneider M; Chevallier B; Goupil A; Chauvergne J
    Am J Clin Oncol; 1994 Apr; 17(2):97-102. PubMed ID: 8141114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.